Cryosite Limited

Belkins
Cryosite specialises in tailored clinical trial logistics, cold and ultra cold storage. We partner with clients across the globe including; research institutes and hospital, medical, pharmaceutical, veterinary and biotechnology industries.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BIODURO LAUNCHES NEW ANTIBODY & CELL THERAPY DISCOVERY SERVICES

BioSpace | March 02, 2020

news image

BioDuro LLC, a leading global life sciences contract research and development organization, announced today that it has broadly launched new antibody- and cell-based therapy discovery services. The services have already been validated by early-access partners that have advanced several biologics-based therapies into the clinic. The Biologics Discovery team at BioDuro has more than 40 scientists and is led by a pharma- and biotech-experienced team with more than 100 years of combined biologics ex...

Read More

BIOTECHNOLOGY LEADER LUMINULTRA SUBMITS COVID-19 CLINICAL DIAGNOSTIC TESTING KIT FOR REGULATORY AUTHORIZATION IN U.S., CANADA

LuminUltra | September 14, 2020

news image

Canada-based biotechnology front-runner LuminUltra announced today that it has submitted its GeneCount® COVID-19 RT-qPCR Assay Kit (COVID-19 Assay) to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) and to Health Canada for an Interim Order (IO). With authorization to use this key testing component, LuminUltra, a leader in field-based molecular diagnostic testing for over 20 years, will provide a complete clinical COVID-19 testing solution that can be custom...

Read More

MEDICAL

SOSEI HEPTARES' COVID-19 PROGRAM IDENTIFIES POTENT BROAD SPECTRUM ANTI-VIRAL SMALL MOLECULES FOR FURTHER DEVELOPMENT

Sosei Heptares | November 21, 2020

news image

Sosei Group Corporation ("the Company") (TSE: 4565) announces a progress update for its R&D program focused on the design and development of novel drugs targeting the SARS-CoV-2 coronavirus and to treat COVID-19.The program was initiated in April 2020. To date, the Company has applied its world-leading structure-based drug design (SBDD) capabilities and cutting-edge technologies to precision-design new inhibitors of the SARS-CoV-2 Mpro protease, which plays a crucial role in ...

Read More

INDUSTRIAL IMPACT

BIODURO-SUNDIA ACQUIRES 2ND US-BASED COMMERCIAL DRUG PRODUCT MANUFACTURING FACILITY ALONG WITH COMMERCIAL SUPPLY AGREEMENT

BioDuro-Sundia | November 09, 2021

news image

BioDuro-Sundia, a leading drug discovery and development services organization backed by Advent International, announced today it has entered into a definitive agreement to acquire a fully-operational 45,000 ft2 commercial oral solid dose drug product manufacturing facility located at 9601 Jeronimo Road, Irvine, CA. As part of the acquisition, BioDuro-Sundia will employ most of the current staff and provide continuous operations to support production of multiple existing products through a comme...

Read More
news image

BIODURO LAUNCHES NEW ANTIBODY & CELL THERAPY DISCOVERY SERVICES

BioSpace | March 02, 2020

BioDuro LLC, a leading global life sciences contract research and development organization, announced today that it has broadly launched new antibody- and cell-based therapy discovery services. The services have already been validated by early-access partners that have advanced several biologics-based therapies into the clinic. The Biologics Discovery team at BioDuro has more than 40 scientists and is led by a pharma- and biotech-experienced team with more than 100 years of combined biologics ex...

Read More
news image

BIOTECHNOLOGY LEADER LUMINULTRA SUBMITS COVID-19 CLINICAL DIAGNOSTIC TESTING KIT FOR REGULATORY AUTHORIZATION IN U.S., CANADA

LuminUltra | September 14, 2020

Canada-based biotechnology front-runner LuminUltra announced today that it has submitted its GeneCount® COVID-19 RT-qPCR Assay Kit (COVID-19 Assay) to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) and to Health Canada for an Interim Order (IO). With authorization to use this key testing component, LuminUltra, a leader in field-based molecular diagnostic testing for over 20 years, will provide a complete clinical COVID-19 testing solution that can be custom...

Read More
news image

MEDICAL

SOSEI HEPTARES' COVID-19 PROGRAM IDENTIFIES POTENT BROAD SPECTRUM ANTI-VIRAL SMALL MOLECULES FOR FURTHER DEVELOPMENT

Sosei Heptares | November 21, 2020

Sosei Group Corporation ("the Company") (TSE: 4565) announces a progress update for its R&D program focused on the design and development of novel drugs targeting the SARS-CoV-2 coronavirus and to treat COVID-19.The program was initiated in April 2020. To date, the Company has applied its world-leading structure-based drug design (SBDD) capabilities and cutting-edge technologies to precision-design new inhibitors of the SARS-CoV-2 Mpro protease, which plays a crucial role in ...

Read More
news image

INDUSTRIAL IMPACT

BIODURO-SUNDIA ACQUIRES 2ND US-BASED COMMERCIAL DRUG PRODUCT MANUFACTURING FACILITY ALONG WITH COMMERCIAL SUPPLY AGREEMENT

BioDuro-Sundia | November 09, 2021

BioDuro-Sundia, a leading drug discovery and development services organization backed by Advent International, announced today it has entered into a definitive agreement to acquire a fully-operational 45,000 ft2 commercial oral solid dose drug product manufacturing facility located at 9601 Jeronimo Road, Irvine, CA. As part of the acquisition, BioDuro-Sundia will employ most of the current staff and provide continuous operations to support production of multiple existing products through a comme...

Read More